Whitepaper: BRCA reverse frameshifts as a mechanism for resistance to PARP inhibitors

Inactivating variants in BRCA1 and 2, such as frameshifts (fs), are clinically approved biomarkers for cancer treatment with PARP inhibitors, for example Olaparib. Fs variants cause a changed protein sequence and typically render the protein non-functional. In contrast, reverse fs variants in the BRCA genes are a common resistance mechanism to treatment with PARP inhibitors. We show here how MH Guide can help you instantly detect both types of variants in a tumor.